论文部分内容阅读
目的研究孟鲁司特钠联合布地奈德治疗支气管哮喘的临床疗效。方法选取2007-03-2009-09来四川省肿瘤医院治疗的支气管哮喘急性发作患者240例,随机分为对照组和治疗组,每组120例。对照组给予常规治疗,治疗组在对照组的基础上加用孟鲁司特钠和布地奈德,两组疗程为10d。疗程结束后,评价两组患者的总体疗效及肺功能的改善状况。结果对照组总有效率为85.83%,治疗组总有效总有效率为95.00%,两组患者总有效率较高,差异有统计学意义(P<0.05);与治疗前比较,治疗后两组患者的FEV1/FVC、PEF均显著升高,差异有统计学意义(P<0.05);与对照组比较,治疗组患者的FEV1/FVC、PEF升高更为明显,两组比较差异有统计学意义(P<0.05)。结论孟鲁司特钠联合布地奈德是治疗支气管哮喘的有效方法,值得临床应用。
Objective To study the clinical efficacy of montelukast combined with budesonide in the treatment of bronchial asthma. Methods From March 2007 to September 2009, 240 acute bronchial asthma patients treated in Sichuan Cancer Hospital were randomly divided into control group and treatment group, with 120 cases in each group. The control group was given routine treatment. The treatment group added montelukast sodium and budesonide on the basis of the control group, and the two courses of treatment were 10 days. After the end of the course of treatment, the overall efficacy and improvement of lung function were evaluated in both groups. Results The total effective rate of the control group was 85.83%, and the total effective rate of the treatment group was 95.00%. The total effective rate of the two groups was higher, the difference was statistically significant (P <0.05). Compared with before treatment, the two groups The FEV1 / FVC and PEF in patients were significantly increased (P <0.05). Compared with the control group, the FEV1 / FVC and PEF increased more significantly in the treatment group, the difference was statistically significant Significance (P <0.05). Conclusion Montelukast combined with budesonide is an effective method for the treatment of bronchial asthma, which is worthy of clinical application.